Introduction: Anemia is a common complication of malignant lymphomas, which could be a direct consequence of the disease or secondary to the myelosupressive chemotherapy. The aim of this study was to assess the effect of erythropoietin to treat anemia. The main objectives were to demonstrate increases in hemoglobin levels and the existence of an association between symptom relief and treatment. Material and method: In the Clinical Hematology and BMT Unit Tîrgu Mureș we performed an analytical, observational study to assess the role of erythropoietin treatment in malignant lymphoma related anemia. This linear, retrospective study included 127 patients diagnosed and treated with malignant lymphoma between January 1 st , 2007 and December 30, 2011. The 127 patients were divided into two groups: a group of patients (n = 88) who were treated with erythropoietin and the other group (n = 39) who did not receive this treatment. Patients included in the study received treatment with epoetin beta 40,000 IU/week. We followed the hemoglobin level and the symptomatology at baseline and after 4 weeks. Results: Patients who received treatment with erythropoietin had a 7.12 times higher possibility of being asymptomatic than patients who did not receive this treatment. The hemoglobin concentration of patients with erythropoietin treatment increased signifi cantly (p <0.0001) compared to the patients who did not receive this treatment. Conclusion: Effective treatment of anemia is an important aim in the management of patients with malignant lymphomas, because it increases their hemoglobin concentration, decreases the need of transfusion and maintains an acceptable quality of life.
Introduction
Anemia is a common complication of malignant lymphomas, which could be a direct consequence of the disease or secondary to the myelosupressive chemotherapy [1, 2, 3] . Th is may be due to the reduction of erythropoesis, manifested by reduction of erythrocyte half-life, poor iron reutilization by the bone marrow and inadequate response to erythropoetin with reduced endogenous erythropoetin levels [4, 5, 6] . Anemia may have a signifi cantly negative eff ect on the quality of life of patients suff ering from malignant lymphoma, producing symptoms such as dizziness, fatigue, weakness, nausea, headache and depression [7] .
Th e human erythropoietin is an acidic glycoproteinhormone with a 34,000 molecular weight synthesized mainly in the kidney by specialized cells and to a minor degree in the liver [8] . Tissue hypoxia triggers the synthesis and the release of erythropoietin into the blood. Erythropoietin is the primary regulator of human erythropoiesis and has two major functions: stimulating proliferation of erythroid progenitor cells and maintaining their viability by inhibiting their apoptosis [5, 9] . In 1993, the use of erythropoietin was approved by the FDA for the treatment of anemia in cancer patients. Th ree types of erythropoietin produced by recombinant DNA technology are used: epoetin alfa, epoetin beta, and darbepoetin [8, 10] .
Th e aim of this study was to assess the eff ect of erythropoietin to treat anemia. Th e main objectives were to demonstrate increases in hemoglobin levels and the existence of association between symptoms relief and treatment, and the secondary objective was to evaluate the need of transfusion. We hypothesized that erythropoietin treatment increases hemoglobin levels in malignant lymphoma patients and improves the symptoms caused by anemia.
Material and method
We performed an analytical, observational study to assess the role of erythropoietin treatment in malignant lymphoma related anemia. For data collection we used preexistent medical records. Th is linear, retrospective study was carried out in the Clinical Hematology and BMT Unit of Tîrgu Mureș and included 127 patients diagnosed and treated with malignant lymphoma between January 1 st , 2007 and December 30, 2011. Patients with the following criteria were included in the study: Hb <11 g/dl, serum ferritine level in normal limits and the transferrin saturation >20%, accusing dizziness, fatigue, weakness, nausea, headache and depression. Exclusion criteria were: patients who had other types of anemia with ferritine level below the lower Correspondence to: Aranka Kurtus E-mail: kurtus.aranka@gmail.com limit of normal reference range and other disorders that can cause the above mentioned complaints. Th e 127 patients were divided into two groups, established by the case-control model: a group of patients (n = 88) who were treated with erythropoietin and the other group (n = 39) who due to objective or subjective reasons did not receive this treatment. Patients included in the study received treatment with epoetin beta 40,000 IU/week. We followed the hemoglobin level and the symptomatology at baseline and after 4 weeks.
Th e obtained qualitative values were introduced in a contingency table, in GraphPad InStat statistical programme and the Chi square test was performed and the results were supervised by the Fisher test. Th e quantitative, continuous variables have been subjected to a rigorous statistical analysis. Distribution normality was verifi ed using continuous numeric variables Kosmogorov-Smirnov test. Diff erences between continuous quantitative variables which did not respect the condition of normality were further analyzed using the Mann-Whitney U test for unpaired, non-parametric data. A value of p <0.05 was considered statistically signifi cant.
Results
In the studied groups men predominated, the men:women ratio was 1.2:1. Th e mean age of the patients was 60.24 years (range 34-76 years).
Anemia was present in 33% of malignant lymphoma patients at the moment of diagnosis and in 67% of them it has developed during antineoplastic therapy.
Chi Th e mean hemoglobin level at baseline in the erythropoietin group (n = 88) was 8.84 g/dl (SD 1.044, 95% CI: 8.597-9.040) and in the other group it was 8.79 g/dl (SD 1.035 , 95% CI: 8.462-9.133). Th e diff erence was not statistically signifi cant (p = 0.8750).
We repeated the statistical analysis after four weeks of therapy with the following results: in the erythropoietin group (n = 88) the mean hemoglobin level was 9.74 g/dl (SD 1.090, 95% CI: 9.516-9.976) and in the untreated group it was 8.81 g/dl (SD 1.060 , 95% CI: 8.500-9.187). Th e diff erence was statistically signifi cant (p <0.0001).
Th e proportion of patients receiving red blood cell transfusions during the study period was 15.90% in the erythropoietin group (n = 14) and 43.58% (n = 17) in the control group. In the erythropoietin group 25 units of red blood cell were used, and 27 units in the control group.
Discussions
Anemia is frequent in cancer patients and its incidence increases with chemotherapy. In hematological malignancies, the prevalence of anemia is almost double than in solid tumors [11] . Neoplastic bone marrow infi ltration and chemotherapy seem to play a major role in the pathogenesis of anemia associated with malignant lymphomas. According to other studies, an estimated 30-40% of malignant lymphoma patients are anemic at the time of diagnosis, with the incidence rising to 70% during chemotherapy [12] . Th is was confi rmed by the results of the present study, which shows that anemia was present in 33% of the patients at the moment of diagnosis and in 67% of them it has developed during antineoplastic therapy. Malignant lymphomas promote infl ammatory cytokine production, which suppresses erythropoesis and erythropoetin production [13] . Data from many studies indicate that treatment of anemic patients with erythropoesis stimulating agents improves erythropoiesis, increases the hemoglobin concentration, decreases the need of transfusion, and also improves their quality of life [8, 14, 15, 16] . Th e obtained results show that the diff erence between mean hemoglobin level after four weeks after onset of therapy was extremely signifi cant (p <0.0001), and hemoglobin levels at week four ranged from 8.81 g/dl (SD 1.044) to 9.74 g/dl (SD 1.090).
Anemia is a major reversible cause of cancer-related fatigue, has a negative impact upon the quality of life and is a negative prognosis factor regarding general survival [13, 17, 18] . Our study suggests that improving hemoglobin level may improve the patient's symptomatology caused by anemia. Th ere are highly signifi cant correlations between symptoms at 1 month after the treatment and the treatment applied (p <0.0001). Th e possibility of being asymptomatic in patients who received treatment with erythropoietin is 7.12 times higher (OR = 7.12) than in patients who did not receive this treatment. Erythropoietin stimulating agents therapy is well tolerated, provides important clinical benefi ts for lymphoma patients with anemia by reducing the need for red blood cell transfusions and exposure to associated risks. Transfusions can cause many adverse reactions, like febrile non-hemolytic transfusion reaction, bacterial and viral infection, acute hemolytic reaction, anaphylactic reaction, transfusion associated acute lung injury, volume overload, iron overload, post transfusional purpura and delayed hemolytic reaction [17, 19, 20] . All this can be avoided if the severe anemia development is prevented with erythropoietin stimulating agents. In our study the proportion of patients receiving transfusions was signifi cantly lower in the erythropoietin group than in the control group. Among patients who were treated with erythropoietin the median transfusion volume decreased considerably compared to the control group. Similar results have been reported by others in randomized recombinant human erythropoietin studies. Th ese studies showed that early initiation of erythropoietin treatment can lead to a reduction in the costs associated with red blood cell transfusion [11, 20, 21] .
Conclusions
Eff ective treatment of anemia is an important aim in the management of patients with malignant lymphomas, in order to maintain an acceptable quality of life. In patients with malignant lymphoma and anemia, erythropoietin increases hemoglobin levels, thus reducing the need for blood transfusion and improving the quality of life. Recombinant human erthropoietin is a promising therapeutic opportunity for treating malignant lymphoma associated anemia.
